70 related articles for article (PubMed ID: 35372330)
1. Immunotherapeutic value of NUSAP1 associated with bladder cancer through a comprehensive analysis of 33 human cancer cases.
Wen X; Hou J; Chu Y; Liao G; Wu G; Fang S; Xiao S; Qiu L; Xiong L
Am J Cancer Res; 2024; 14(3):959-978. PubMed ID: 38590423
[TBL] [Abstract][Full Text] [Related]
2. Deciphering the vital roles and mechanism of m5C modification on RNA in cancers.
Zheng L; Duan Y; Li M; Wei J; Xue C; Chen S; Wei Q; Tang F; Xiong W; Zhou M; Deng H
Am J Cancer Res; 2023; 13(12):6125-6146. PubMed ID: 38187052
[TBL] [Abstract][Full Text] [Related]
3. Function of m
Yang S; Zhou D; Zhang C; Xiang J; Xi X
Cancer Biol Ther; 2023 Dec; 24(1):2263921. PubMed ID: 37800580
[TBL] [Abstract][Full Text] [Related]
4. NOP2-mediated m5C Modification of c-Myc in an EIF3A-Dependent Manner to Reprogram Glucose Metabolism and Promote Hepatocellular Carcinoma Progression.
Zhang H; Zhai X; Liu Y; Xia Z; Xia T; Du G; Zhou H; Franziska Strohmer D; Bazhin AV; Li Z; Wang X; Jin B; Guo D
Research (Wash D C); 2023; 6():0184. PubMed ID: 37398932
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
[TBL] [Abstract][Full Text] [Related]
6. Exosomes: A potential tool for immunotherapy of ovarian cancer.
Gong X; Chi H; Strohmer DF; Teichmann AT; Xia Z; Wang Q
Front Immunol; 2022; 13():1089410. PubMed ID: 36741380
[TBL] [Abstract][Full Text] [Related]
7. RNA Modifications Meet Tumors.
Yang Z; Zhang S; Xia T; Fan Y; Shan Y; Zhang K; Xiong J; Gu M; You B
Cancer Manag Res; 2022; 14():3223-3243. PubMed ID: 36444355
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of m5C regulatory genes in hepatocellular carcinoma.
Yang X; Yang F; Lan L; Wen N; Li H; Sun X
Front Genet; 2022; 13():972043. PubMed ID: 36105093
[No Abstract] [Full Text] [Related]
9. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
10. Identification of genomic features associated with immunotherapy response in gastrointestinal cancers.
He Y; Liu ZX; Jiang ZH; Wang XS
World J Gastrointest Oncol; 2019 Apr; 11(4):270-280. PubMed ID: 31040893
[TBL] [Abstract][Full Text] [Related]
11. Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types.
Liu T; Zhang J; Lin C; Liu G; Xie G; Dai Z; Yu P; Wang J; Guo L
Front Cell Dev Biol; 2022; 10():839136. PubMed ID: 35372330
[No Abstract] [Full Text] [Related]
12. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
Mo Z; Li P; Cao Z; Zhang S
Front Immunol; 2021; 12():564948. PubMed ID: 34290693
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive pan-cancer analysis of 33 human cancers reveals immunotherapeutic value of focal adhesion tyrosine kinase.
Shi Y; Ju M; Zhang Y; Liang L; Sun X; Di X
Medicine (Baltimore); 2024 Mar; 103(12):e37362. PubMed ID: 38518034
[TBL] [Abstract][Full Text] [Related]
14. m5C regulator-mediated methylation modification phenotypes characterized by distinct tumor microenvironment immune heterogenicity in colorectal cancer.
Chen Z; Li Q; Lin Y; Lin S; Gao J; Chen S
Sci Rep; 2023 Jul; 13(1):11950. PubMed ID: 37488178
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
